PATENT CLAIM ANALYSIS

Application Number: 16109824
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "639000"]

Abstract:
Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.

Claim (Index 2):
The method as recited in  claim 1 , wherein the symptoms in a relapse of multiple sclerosis are decreased.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 96.0
- Lexical Diversity: 2.05556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14759599', '14480847', '13354076', '13984124', '14033738']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7654318537695941
- 35 USC 102 Novelty (BERT): 0.6197501573231285
- Combined Prediction Score: 0.7508636841249476
- Mean Citation Score: 340.537118
- Max Citation Score: 743.6402
- Similarity Product: 478.10808481411937

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test